Furthermore, previous study has indicated that CPH could be a novel agent that enhances the efficacy of HDAC inhibitors in eradicating cancer cells (Paoluzzi et al. 2009), suggesting that CPH may be an epigenetic modifier to exert its anti-tumor effects. This evidence concerns the gene HDAC9 and cancer.